Gemfibrozil
From Wikipedia, the free encyclopedia
Gemfibrozil
|
|
Systematic (IUPAC) name | |
5-(2,5-dimethylphenoxy)-2,2-dimethyl-pentanoic acid | |
Identifiers | |
CAS number | |
ATC code | C10 |
PubChem | |
DrugBank | |
Chemical data | |
Formula | C15H22O3 |
Mol. mass | 250.333 g/mol |
Pharmacokinetic data | |
Bioavailability | Close to 100% |
Protein binding | 95% |
Metabolism | Hepatic (CYP3A4) |
Half life | 1.5 hours |
Excretion | Renal 94% Feces 6% |
Therapeutic considerations | |
Pregnancy cat. |
Category C |
Legal status |
By Prescription |
Routes | Oral |
Gemfibrozil is the generic name for an oral drug used to lower lipid levels. It belongs to a group of drugs known as fibrates. It is most commonly sold as the brand name, Lopid. Other brand names include Jezil and Gen-Fibro.
Contents |
[edit] Actions
- Increases activity of Peroxisome proliferator-activated receptor-alpha (PPARα), a receptor which is involved in metabolism of carbohydrates and fats, as well as adipose tissue differentiation. This increases synthesis of lipoprotein lipase therefore increasing clearance of triglycerides.
[edit] Therapeutic effects
- Reduce triglyceride levels
- Reduce Very low density lipoprotein (VLDL) levels
- Modest reduction of Low density lipoprotein (LDL) levels
- Moderate increase in High density lipoprotein (HDL) levels
[edit] Nontherapeutic effects and toxicities
- GI distress
- Musculoskeletal pain
- Increased incidence of gallstones
- Hypokalemia
- Increased risk of cancer[1]
[edit] Indications
- Hyperlipidemia (Type III): Gemfibrozil is the drug of choice for therapy.
- Hypertriglyceridemia (Type IV): Gemfibrozil, though not as effective as niacin, is better tolerated.
[edit] Contraindications and Precautions
- Gemfibrozil should not be given to these patients:
- Hepatic dysfunction
- Renal dysfunction
- Gemfibrozil should be used with caution in these higher risk categories:
- Biliary tract disease
- pregnant women
- obese patients
- Native Americans
[edit] Drug Interactions
- Anticoagulants: Gemfibrozil potentiates the action of coumadin and indanedione anticoagulants.
- Statin drugs: Concomidant administration of fibrates (including gemfibrozil) with statin drugs increases the risk of muscle cramping, myopathy, and rhabdomyolysis.
[edit] External links
- DrugBank Gemfibrozil
- NIH Gemfibrozil Drug Info}
- Lopid International Study
- Safety of Statins - Circulation. 2004;109:III-50 – III-57
|